A Multicenter Study of Clinicopathology and Immunohistochemical Distinction between Adult and Pediatric Large B-Cell Lymphoma

References

• Vaidya R, Witzig TE. Prognostic factors for diffuse large B-cell lymphoma in the R(X)CHOP era. Ann Oncol. 2014;25(11):2124–33. doi:10.1093/annonc/mdu109.
   PubMed Web of Science ®Google Scholar
• Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403(6769):503–11. doi:10.1038/35000501.
   PubMed Web of Science ®Google Scholar
• Choi WWL, Weisenburger DD, Greiner TC, Piris MA, Banham AH, Delabie J, Braziel RM, Geng H, Iqbal J, Lenz G, et al. A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res. 2009;15(17):5494–502.89055. doi:10.1158/1078-0432.CCR-09-0113.
   PubMed Web of Science ®Google Scholar
• Raetz E, Perkins S, Davenport V, Cairo MS. B large-cell lymphoma in children and adolescents. Cancer Treat Rev. 2003;29(2):91–8. doi:10.1016/S0305-7372(02)00108-1.
   PubMed Web of Science ®Google Scholar
• Burkhardt B, Zimmermann M, Oschlies I, Niggli F, Mann G, Parwaresch R, Riehm H, Schrappe M, Reiter A. The impact of age and gender on biology, clinical features and treatment outcome of non-Hodgkin lymphoma in childhood and adolescence. Br J Haematol. 2005;131(1):39–49. doi:10.1111/j.1365-2141.2005.05735.x.
   PubMed Web of Science ®Google Scholar
• Hasserjian R, Le Beau M, List A, Thiele J. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: International Agency for Research on Cancer; 2017. p. 98.
   Google Scholar
• National Comprehensive Cancer Network. B-Cell Lymphomas (Version 4.2022) [2022 June 9]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf
   Google Scholar
• Chuang W-Y, Chang H, Chang G-J, Wang T-H, Chang Y-S, Wang T-H, Yeh C-J, Ueng S-H, Chien H-P, Chang C-Y, et al. Pleomorphic mantle cell lymphoma morphologically mimicking diffuse large B cell lymphoma: common cyclin D1 negativity and a simple immunohistochemical algorithm to avoid the diagnostic pitfall. Histopathology. 2017;70(6):986–99. Epub 20170310. doi:10.1111/his.13161.
   PubMed Web of Science ®Google Scholar
• Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275–82. doi:10.1182/blood-2003-05-1545.
   PubMed Web of Science ®Google Scholar
• Lu T-X, Miao Y, Wu J-Z, Gong Q-X, Liang J-H, Wang Z, Wang L, Fan L, Hua D, Chen Y-Y, et al. The distinct clinical features and prognosis of the CD10(+)MUM1(+) and CD10(-)Bcl6(-)MUM1(-) diffuse large B-cell lymphoma. Sci Rep. 2016;6:20465. doi:10.1038/srep20465.
   PubMed Web of Science ®Google Scholar
• Meyer PN, Fu K, Greiner TC, Smith LM, Delabie J, Gascoyne RD, Ott G, Rosenwald A, Braziel RM, Campo E, et al. Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab. J Clin Oncol. 2011;29(2):200–7. doi:10.1200/JCO.2010.30.0368.
   PubMed Web of Science ®Google Scholar
• Costa LJ, Feldman AL, Micallef IN, Inwards DJ, Johnston PB, Porrata LF, Ansell SM. Germinal center B (GCB) and non-GCB cell-like diffuse large B cell lymphomas have similar outcomes following autologous haematopoietic stem cell transplantation. Br J Haematol. 2008;142(3):404–12. doi:10.1111/j.1365-2141.2008.07207.x.
   PubMed Web of Science ®Google Scholar
• Muris JJF, Meijer CJLM, Vos W, van Krieken JHJM, Jiwa NM, Ossenkoppele GJ, Oudejans JJ. Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma. J Pathol. 2006;208(5):714–23. doi:10.1002/path.1924.
   PubMed Web of Science ®Google Scholar
• Seki R, Ohshima K, Fujisaki T, Uike N, Kawano F, Gondo H, Makino S, Eto T, Moriuchi Y, Taguchi F, et al. Prognostic impact of immunohistochemical biomarkers in diffuse large B-cell lymphoma in the rituximab era. Cancer Sci. 2009;100(10):1842–7. doi:10.1111/j.1349-7006.2009.01268.x.
   PubMed Web of Science ®Google Scholar
• Chang S-T, Chen S-W, Ho C-H, Kuo C-C, Sakata S, Takeuchi K, Chuang S-S. Immunophenotypic and genetic characteristics of diffuse large B-cell lymphoma in Taiwan. J Formos Med Assoc. 2016;115(11):961–7. doi:10.1016/j.jfma.2016.09.006.
   PubMed Web of Science ®Google Scholar
• Yoon SO, Jeon YK, Paik JH, Kim WY, Kim YA, Kim JE, Kim CW. MYC translocation and an increased copy number predict poor prognosis in adult diffuse large B-cell lymphoma (DLBCL), especially in germinal centre-like B cell (GCB) type. Histopathology. 2008;53(2):205–17. doi:10.1111/j.1365-2559.2008.03076.x.
   PubMed Web of Science ®Google Scholar
• Li T, Medeiros LJ, Lin P, Yin H, Littlejohn M, Im W, Lennon PA, Hu P, Jorgensen JL, Liang M, et al. Immunohistochemical profile and fluorescence in situ hybridization analysis of diffuse large B-cell lymphoma in northern China. Arch Pathol Lab Med. 2010;134(5):759–65. doi:10.1043/1543-2165-134.5.759.
   PubMed Web of Science ®Google Scholar
• Al-Abbadi MA, Hattab EM, Tarawneh MS, Amr SS, Orazi A, Ulbright TM. Primary testicular diffuse large B-cell lymphoma belongs to the nongerminal center B-cell-like subgroup: a study of 18 cases. Mod Pathol. 2006;19(12):1521–7. doi:10.1038/modpathol.3800691.
   PubMed Web of Science ®Google Scholar
• Camilleri-Broët S, Crinière E, Broët P, Delwail V, Mokhtari K, Moreau A, Kujas M, Raphaël M, Iraqi W, Sautès-Fridman C, et al. A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases. Blood. 2006;107(1):190–6. doi:10.1182/blood-2005-03-1024.
   PubMed Web of Science ®Google Scholar
• Murase T, Yamaguchi M, Suzuki R, Okamoto M, Sato Y, Tamaru J-i, Kojima M, Miura I, Mori N, Yoshino T, et al. Intravascular large B-cell lymphoma (IVLBCL): a clinicopathologic study of 96 cases with special reference to the immunophenotypic heterogeneity of CD5. Blood. 2007;109(2):478–85. doi:10.1182/blood-2006-01-021253.
   PubMed Web of Science ®Google Scholar
• Yoshida S, Nakamura N, Sasaki Y, Yoshida S, Yasuda M, Sagara H, Ohtake T, Takenoshita S, Abe M. Primary breast diffuse large B-cell lymphoma shows a non-germinal center B-cell phenotype. Mod Pathol. 2005;18(3):398–405. doi:10.1038/modpathol.3800266.
   PubMed Web of Science ®Google Scholar
• Miles RR, Raphael M, McCarthy K, Wotherspoon A, Lones MA, Terrier-Lacombe MJ, Patte C, Gerrard M, Auperin A, Sposto R, et al. Pediatric diffuse large B-cell lymphoma demonstrates a high proliferation index, frequent c-Myc protein expression, and a high incidence of germinal center subtype: Report of the French-American-British (FAB) international study group. Pediatr Blood Cancer. 2008;51(3):369–74. doi:10.1002/pbc.21619.
   PubMed Web of Science ®Google Scholar
• Oschlies I, Klapper W, Zimmermann M, Krams M, Wacker H-H, Burkhardt B, Harder L, Siebert R, Reiter A, Parwaresch R, et al. Diffuse large B-cell lymphoma in pediatric patients belongs predominantly to the germinal-center type B-cell lymphomas: a clinicopathologic analysis of cases included in the German BFM (Berlin-Frankfurt-Munster) multicenter trial. Blood. 2006;107(10):4047–52. doi:10.1182/blood-2005-10-4213.
   PubMed Web of Science ®Google Scholar
• Engelhard M, Brittinger G, Huhn D, Gerhartz HH, Meusers P, Siegert W, et al. Subclassification of diffuse large B-cell lymphomas according to the Kiel classification: distinction of centroblastic and immunoblastic lymphomas is a significant prognostic risk factor. Blood. 1997;89(7):2291–7. Epub 1997/04/01.
   PubMed Web of Science ®Google Scholar
• Song M-K, Chung J-S, Shin D-Y, Lim S-N, Lee G-W, Choi J-C, Park W-Y, Oh S-Y. Tumor necrosis could reflect advanced disease status in patients with diffuse large B cell ­lymphoma treated with R-CHOP therapy. Ann Hematol. 2017;96(1):17–23. doi:10.1007/s00277-016-2822-8.
   PubMed Web of Science ®Google Scholar
• Cairo M, Auperin A, Perkins SL, Pinkerton R, Harrison L, Goldman S, Patte C. Overall survival of children and adolescents with mature B cell non-Hodgkin lymphoma who had refractory or relapsed disease during or after treatment with FAB/LMB 96: a report from the FAB/LMB 96 study group. Br J Haematol. 2018;182(6):859–69. doi:10.1111/bjh.15491.
   PubMed Web of Science ®Google Scholar
• Patte C, Auperin A, Gerrard M, Michon J, Pinkerton R, Sposto R, Weston C, Raphael M, Perkins SL, McCarthy K, et al. Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients. Blood. 2007;109(7):2773–80. doi:10.1182/blood-2006-07-036673.
   PubMed Web of Science ®Google Scholar
• Frost M, Newell J, Lones MA, Tripp SR, Cairo MS, Perkins SL. Comparative immunohistochemical analysis of pediatric Burkitt lymphoma and diffuse large B-cell lymphoma. Am J Clin Pathol. 2004;121(3):384–92. doi:10.1309/8WYN-VUTG-V9RP-HUQH.
   PubMed Web of Science ®Google Scholar
• Bellan C, Stefano L, Giulia de F, Rogena EA, Lorenzo L. Burkitt lymphoma versus diffuse large B-cell lymphoma: a practical approach. Hematol Oncol. 2009;27(4):182–5. doi:10.1002/hon.914.
   PubMed Web of Science ®Google Scholar
• Poirel HA, Cairo MS, Heerema NA, Swansbury J, Aupérin A, Launay E, Sanger WG, Talley P, Perkins SL, Raphaël M, et al. Specific cytogenetic abnormalities are associated with a significantly inferior outcome in children and adolescents with mature B-cell non-Hodgkin’s lymphoma: results of the FAB/LMB 96 international study. Leukemia. 2009;23(2):323–31. doi:10.1038/leu.2008.312.
   PubMed Web of Science ®Google Scholar
• Akasaka T, Akasaka H, Ueda C, Yonetani N, Maesako Y, Shimizu A, Yamabe H, Fukuhara S, Uchiyama T, Ohno H, et al. Molecular and clinical features of non-Burkitt’s, diffuse large-cell lymphoma of B-cell type associated with the c-MYC/immunoglobulin heavy-chain fusion gene. J Clin Oncol. 2000;18(3):510–8. doi:10.1200/JCO.2000.18.3.510.
   PubMed Web of Science ®Google Scholar
• Kawasaki C, Ohshim K, Suzumiya J, Kanda M, Tsuchiya T, Tamura K, Kikuchi M. Rearrangements of bcl-1, bcl-2, bcl-6, and c-myc in diffuse large B-cell lymphomas. Leuk Lymphoma. 2001;42(5):1099–106. doi:10.3109/10428190109097730.
   PubMed Web of Science ®Google Scholar